Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial

Title: Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial
Authors: Hall, Peter S; Swinson, D.; Lord, S.; Handforth, C.; Cairns, D.; Marshall, H.; Petty, R.; Bennett, M.; Velikova, G.; Seymour, M.T.
Source: Hall, P S, Swinson, D, Lord, S, Handforth, C, Cairns, D, Marshall, H, Petty, R, Bennett, M, Velikova, G & Seymour, M T 2019, 'Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial', Annals of Oncology, vol. 30, mdz394.037, pp. v879-v880. https://doi.org/10.1093/annonc/mdz394.037
Publication Year: 2019
Collection: Discovery - University of Dundee Online Publications
Description: Background Many pts with aGOAC are elderly and/or frail. GO2 [ASCO 2019 #4006] found that lower dose OxaliplatinCapecitabine (OCap) led to non-inferior progression free survival, less toxicity and better patient-centred outcomes using a novel composite endpoint ‘Overall Treatment Utility’. QoL endpoints were chosen to reflect the balance between benefits and harms of the three dose levels and to help patients understand likely implications of treatment for shared decision making. Methods Eligible pts unsuitable for full-dose 3-drug chemotherapy due to frailty, but fit for OCap. Baseline assessment included QoL; symptoms; functional scales; comorbidity; frailty. Randomization was 1:1:1 to dose Level (Lvl) A (Ox 130 mg/m2d1, Cap 625 mg/m2bd d1-21, q21d), B (80% Lvl A doses) or C (60% Lvl A doses) until progression or decision to stop. An alternative randomisation option where chemo benefit was considered uncertain (‘uc’) was between OCap Lvl C and Best Supportive Care (BSC). QoL (EQ-VAS) was measured weekly during chemotherapy. QoL (EQ-5D), Fatigue (EORTC QLQ-C30 Fatigue scale) were measured 9-weekly for 1 year. QoL endpoints were analysed descriptively as pre-defined in the statistical analysis plan. Results 558 pts were enrolled, 2014-17, 61 UK centres, of which 45 pts were in the uc randomisation.
Document Type: article in journal/newspaper
Language: English
ISSN: 0923-7534; 1569-8041
Relation: info:eu-repo/semantics/altIdentifier/pissn/0923-7534; info:eu-repo/semantics/altIdentifier/eissn/1569-8041
DOI: 10.1093/annonc/mdz394.037
Availability: https://discovery.dundee.ac.uk/en/publications/7750e082-a642-4f59-b4be-a37b41269f2e; https://doi.org/10.1093/annonc/mdz394.037; http://www.sciencedirect.com/science/article/pii/S0923753419603972
Rights: info:eu-repo/semantics/openAccess ; http://www.elsevier.com/about/company-information/policies/open-access-licenses/elsevier-user-license
Accession Number: edsbas.3F42E298
Database: BASE